Navigation Links
InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery
Date:12/4/2009

InhibOx, a leading developer of novel and effective computational methods for drug discovery, has joined forces with MolPort, an innovator in rare chemical trading. MolPort focuses on developing rare chemical trading platform and builds database of commercially available compounds. Now we provide this database and its updates to computational chemists at InhibOx where they incorporate it into the virtual screening procedures. Once they identify suitable lead candidates, MolPort offers to efficiently source these compounds and deliver to the client for testing.

(PRWEB) December 4, 2009 -- InhibOx Ltd (Oxford, UK) and MolPort Ltd (Riga, Latvia) announce a strategic partnership to deliver integration in library design and compound provision.

InhibOx, a leader in drug lead identification and library design software and service, uses breakthrough proprietary technology to offer an on-demand virtual screening capability which has demonstrated dramatically improved results over traditional high throughput screening methods. The company has partnered with MolPort, the innovative compound provision consolidator/specialist.

Together, the two companies are able to provide a new, unique service which delivers novel lead candidates in the form of a rich data set and high quality compound samples. Frequently virtual screening identifies compound sets for testing which must be sourced from multiple suppliers, imposing a logistical problem, especially for smaller companies. This integrated service removes these bottlenecks, allowing much improved access to commercially available molecules.

Dr. Paul Finn, CEO of InhibOx, sees this as an important breakthrough in outsourced screening services. “InhibOx goes further than anyone else in value-added virtual screening, and the results bear this out. By adding library sample provision to the service, through MolPort’s highly responsive capability, we offer a unique integrated service which accelerates lead design and lowers the management costs for all customers”.

“Our goal is to make chemical buying as simple as buying a book on Amazon. Screening compound sourcing can be especially complex as it often involves locating suppliers for a large number niche products form companies all around the world. Integrating our database of commercially available compounds with InhibOx virtual screening processes enables streamlining of the road from idea to testable compounds in the clients laboratory. Partnering with InhibOx has allowed us to tailor our services for the needs of computational chemists.” said Dr. Imants Zudans, CEO of MolPort.

About InhibOx:

InhibOx develops novel and effective computational methods for drug discovery to improve the productivity of lead and candidate identification. The company was founded by Professor W. Graham Richards, former Chairman of Chemistry at the University of Oxford and world leading computational chemist. The company grew from the outstandingly successful Screensaver Lifesaver project which involved some 3.5 million personal computers in over 200 countries: the world's biggest computational chemistry experiment finding lead compounds to inhibit cancer targets, anthrax and smallpox. Since then, InhibOx has built up a significant technology platform in computer-aided drug design. Ongoing activities comprise the development of entirely novel computational drug discovery methods; the development of Scopius, a very large and carefully curated database of commercially-available and virtual chemical structures and their delivery to the life science industries.

About MolPort:

MolPort is a rare chemical compound marketplace enabling worry free centralized ordering of chemicals from over 200 companies. To make the marketplace work MolPort has created a world class database of commercially available chemical compounds. The free access online search portal www.molport.com features unmatched advanced chemical structure search capabilities that are especially suited for a sophisticated and demanding user.

# # #

Read the full story at http://www.prweb.com/releases/2009/12/prweb3298024.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. St. Jude Patients and Expert Chefs Join Forces To Create Gingerbread House
2. LeapFish and Make-a-Wish Foundation Join Forces to Raise $10,000 and Tweet an Ill Child's Wish True
3. Big Brothers Big Sisters Military Mentor Featured in New Civic Enterprises Report on Leadership and Our Armed Forces
4. Drug industry, nonprofits join forces to fight worlds neglected diseases
5. U.S. Army Special Forces Operators Reluctant to Seek Treatment for Posttraumatic Stress Disorder
6. Childrens and Its Physicians Join Forces With Insurers to Accelerate Transformation of Pediatric Care to a More Effective and Efficient Health Care Delivery System
7. MTD Joins Forces with the AHA to Promote Heart Health
8. Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse
9. Engineering center to probe forces that cause cancer to spread
10. Substance Abuse Expert Dr. Drew Joins Forces with the Five Moms to Raise Awareness About OTC Cough Medicine Abuse Among Teens
11. Ford and Labor Leaders Join Forces with March of Dimes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... stories, which come courtesy of leaders in the nursing and health care industry. It ... advocates and associations—namely Abilene Christian University. , As the nursing industry is coming ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting ... and company to wait until March 2017 for an interest rate increase, according to ... College of Business. , “The Federal Open Market Committee (FOMC) dot charts are of ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... thousands of defective respirators, according to court documents and SEC filings. A ... and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... one that has a significant negative impact on long-term patient survival, reports a ... The results, published online this week in the Journal of Thoracic and Cardiovascular ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... FDA 510(k) clearance covers ... for urological and surgical applications Mauna ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, ... US with the 12 th 510(k) clearance ... This new FDA clearance covers Confocal Miniprobes indicated ...
(Date:5/25/2016)... May 25, 2016  Zymo Research Corp. announced ... new reference materials that help researchers obtain the ... to analyses. The rapid growth of the study ... to have standard methods to improve the reproducibility ... inherently exist at every step of the measurement ...
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today ... test for wounds and infections. This test ensures ... and select viruses. The test requires only a ... David G. Bostwick , MD, ... to facilitate wound healing: "We are excited to ...
Breaking Medicine Technology: